SAROJ BRAR: Open Payments
NPI 1487733366 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,780 in 58 payments from 12 companies in 2025. Trend: 2023 $1,608 · 2024 $1,947 · 2025 $2,780
Food & beverage: $2,670Education: $109
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $746 |
| Janssen Pharmaceuticals, Inc | 6 | $556 |
| Teva Pharmaceuticals USA, Inc. | 10 | $427 |
| Alkermes, Inc. | 9 | $347 |
| Vanda Pharmaceuticals Inc. | 5 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $161 |
| Otsuka America Pharmaceutical, Inc. | 2 | $141 |
| ABBVIE INC. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
Products named: COBENFY, INVEGA SUSTENNA, ARISTADA, AUSTEDO XR, CAPLYTA, REXULTI, UZEDY, FANAPT.
Industry payments across OH — which companies pay providers there.
